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Summary
The development of the percutaneous heart valve (PHV) may become a primary therapeutic
modality for the high risk and inoperable patients with critical symptomatic aortic stenosis. The
first human percutaneous aortic valve implant was performed by our group in April 2002. To
date, more than 500 Cribier-Edwards-PHV have been implanted worldwide using arterial trans-
femoral or trans-apical approach. Data on the retrograde transfemoral approach is growing
with more than 270 patients implanted as of October 2007. Procedural success rate is high (86%)
and the 30-day mortality is 12%. Today, 2 patients are alive at a follow-up of more than 4 years.
The same Cribier-Edwards-PHV can be implanted using trans-apical approach. In this
procedure, PHV is introduced under direct vision into the left ventricle via a mini-thoracotomy.
This obviates the concerns regarding vascular access in the presence of small caliber vessels
and/or vascular occlusive disease. More than 200 patients have been treated with this
approach. In the European experience 30-day mortality is 14%. 
There is intense interest in PHV technology, and there are multiple devices at various stages of
development in animals and humans. The most developed is the CoreValve Revalving®
Technology. More than 350 patients have been treated with this technique. The immediate and
mid-term results with this device are promising with a procedural success of 92% and a 30-day
mortality of 15%. 
The future of this technology and its application is dependent on the continued collaboration
between general internists, cardiologists, surgeons, engineers, and industry.
© 2008 Published by Elsevier Masson SAS.
Résumé
L'implantation percutanée d'une bioprothèse pour le traitement du rétrécissement aortique
dégénératif a fait entrer la cardiologie interventionnelle dans une ère nouvelle et constitue
aujourd'hui un espoir thérapeutique pour un nombre croissant de patients à trop haut risque
chirurgical pour un remplacement aortique conventionnel. Le premier cas d'implantation chez
* H. Eltchaninoff, Service de cardiologie, Hôpital Charles-Nicolle, Université de Rouen, 1, rue de Germont, 76031 Rouen cedex. 
E-mail : Helene.eltchaninoff@chu-rouen.fr
KEYWORDS
Percutaneous heart 
valve;
Aortic stenosis;
Retrograde 
transfemoral 
approach;
Trans-apical 
approach.
MOTS CLÉS
Valve percutanée ;
Sténose aortique ;
Valve percutanée ;
Transcatheter aortic valve implantation: technical aspects, results and indications 127
l'homme a été réalisé en avril 2002 par notre équipe. Depuis, plus de 500 patients ont été
traités à travers le monde avec la valve de Cribier. Les implantations par voie artérielle
fémorale se multiplient avec plus de 270 patients traités. Le taux de succès est de l'ordre de
90 % et la mortalité à 30 jours est de 12 % dans les études multicentriques récentes. Deux
patients ont dépassé les 4 ans de suivi. La même valve peut être implantée par voie-
transapicale, après mini-thoracotomie sous anesthésie générale. Les résultats portent sur plus
de 200 patients avec un taux de mortalité à 30 jours de 14 % dans la série européenne.
L'intérêt pour cette technique est croissant et de nombreux modèles sont en développement.
Plus de 350 patients ont été traités par implantation d'une CoreValve. Les résultats sont
également très prometteurs avec un taux de succès de 92 % et une mortalité à 30 jours de 15 %.
L'avenir de ces technologies et leur application future dépendra de la collaboration étroite
entre médecins traitants, cardiologues, chirurgiens, ingénieurs et industrie.
© 2008 Published by Elsevier Masson SAS.
A definitive non-surgical answer to the problem of resteno-
sis following balloon aortic valvuloplasty (BAV) is under
intense investigation. The development of the percuta-
neous heart valve (PHV) may become a primary therapeutic
modality for the high risk and inoperable patients with cri-
tical symptomatic aortic stenosis (AS). As described in the
EuroHeart Survey on valvular disease [1], patients with val-
vular heart disease are often undertreated. Approximately
one-third of symptomatic patients with severe AS do not
undergo surgical treatment as a consequence of their age or
the presence of left ventricular dysfunction. 
In our center, the concept of catheter based valve replace-
ment emerged during the early 1990s as a potential therapy
for patients with non-surgical calcific AS, and as a possible
solution of the high restenosis rate observed after balloon val-
vuloplasty. In 1994, we confirmed the ability to anchor a bal-
loon expandable stent in the calcified and fibrotic aortic annu-
lus of human cadavers with aortic stenosis. These experiments
also provided the initial data regarding optimal stent length
and diameter. Five years later, with the creation of PVT (Per-
cutaneous Valve Technologies, Fort Lee, NJ, USA), a prototype
PHV was developed and tested in the sheep model [2, 3]. 
The first human percutaneous aortic valve implant was
performed by our group in April 2002 [4]. An initial series of
human implantations for compassionate use followed and
were serially reported [5-7]. Following the acquisition of
PVT by Edwards LifeSciences in 2004, further modifications
of the valve (Cribier-Edwards and Edwards-Sapien percuta-
neous heart valve) and its implantation instruments prece-
ded multicenter clinical trials. The technique was exported
to Canada in 2005 and widely evaluated by John Webb in
Vancouver [8, 9]. To date, more than 500 Cribier-Edwards-
PHV have been implanted worldwide.
This article will provide a current overview of the proce-
dural techniques, results, and future strategies with the Cri-
bier bioprosthesis. The Corevalve Revalving® System (Core-
Valve Inc, Irvine, Ca), another percutaneous valve with a
self-expanding stent will be discussed as well [10-12]. 
Percutaneous heart valve implantation 
using the Cribier-PVT/Edwards 
bioprosthetic valve
The first in man percutaneous aortic valve was implanted
using an antegrade (venous) approach since the patient had
severe occlusive peripheral vascular disease and no suitable
arterial access [4]. Since then, there have been numerous
refinements in the device. With ongoing experience, seve-
ral changes have been introduced in the implantation pro-
tocols. Currently the valve is placed through a retrograde
arterial approach or through a trans-apical minimally inva-
sive surgical approach. 
Percutaneous valve and delivery systems
The Edwards valve delivery system consists of the biopros-
thetic valve, balloon catheter, retroflex catheter, and the
crimping tool (figure 1 and 2). 
The valve
The Cribier-Edwards valve is a trileaflet valve composed
of three equal sections of equine pericardium integrated
into a stainless steel balloon expandable stent frame. A
second generation valve made of bovine pericardium
known as the Edwards Sapien valve has replaced the pre-
vious model (figure 1). A fabric cuff is sewn onto the
frame covering one third of the stent which is oriented
towards the left ventricle when deployed. The original
stent measured 14.5 mm in length and was designed for a
maximal expansion of 23 mm diameter. Due to the varia-
bility of aortic annulus size and an important rate of peri-
valvular leak, a larger stent with a 26 mm diameter and a
16 mm length was introduced. This valve is intended to be
implanted in the subcoronary position, using the native
calcific valve to anchor the stent. Bench testing has esta-
blished a greater than 10 year durability.
The balloon catheter
To deliver and deploy the PHV a custom balloon catheter
manufactured by NuMed (Z-MED II, NuMed, Inc., Hopkinton,
NY, USA) is used. 
The crimping tool
A unique crimping device is used to symmetrically compress
the PHV from its expanded size to its minimal delivery pro-
file. The 23 mm PHV is compatible with a 22F sheath and
the 26 mm PHV with a 24F sheath. 
The retro-flex guiding catheter
This catheter (figure 2) was introduced in 2005 to facilitate
the retrograde delivery of the PHV [8]. Its tip changes
direction when activated by rotation of an external hub
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incorporated into the handle. The PHV assembly protrudes
distally, and is not covered by the guide catheter. The
guide catheter is then used to direct the Retro-Flex cathe-
ter-PHV assembly through the arterial system, around the
aortic arch, and across the aortic valve. This provides a less
traumatic passage of the PHV through a tortuous and
diseased aorta. There is also improved ability to center and
push the PHV assembly across the calcified and stenotic
native valve. This system also allows precise positioning of
the PHV at the aortic annulus. 
Technical aspects for PHV implantation 
using the Cribier-PVT/Edwards valve
The techniques that will be described below include the
antegrade transeptal approach, the retrograde approach,
and the transapical approach that we have used in our
center. Enrollment into one of the approved PHV trials is
necessary to receive the device. Patient prerequisites for
enrollment are: presence of severe symptomatic aortic
valve stenosis (≤ 0.7 cm2, with associated dyspnea class
III/IV by NYHA classification) that are expected to benefit
from isolated valve replacement, surgical refusal for stan-
dard aortic valve replacement, or classification as high
operative risk by a Parsonnet’s score ≥ 30 in the earlier
feasibility studies or logistic Euroscore > 20% in the recent
trials. Major exclusion criteria include the following:
unprotected stenosis of the left main coronary artery not
amenable to percutaneous intervention, prosthetic heart
valves, active infection, active bleeding, coagulopathy.
Patients who cannot be fully dilated with a 23 mm aortic
valvuloplasty balloon (notable waist), have a native aortic
valve annulus size > 25 mm, or < 19 mm are also currently
excluded. 
Figure 1. The Cribier-Edwards Bioprosthesis. From top to bottom and left to right: 1. Side and upper view of the stented valve; 2. the
bioprosthesis in position at mid-part of the balloon before crimping; 3. the crimping phase; 4. a view of the crimped valve over the balloon 
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Figure 2. The Retro-Flex catheter. Its distal end can be deflected
to help advancing the delivery system within the tortuous arterial
access and to centralize the guide wire at the time of native valve
crossing.
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Baseline measurements 
and patient’s premedication
Baseline transthoracic echocardiogram (TTE), right and left
heart catheterization, left ventriculography, supra-aortic
angiography, and coronary angiography are obtained prior to
the planned PHV. This is necessary to determine the severity
of the AS, the diameter of the aortic annulus, left ventricular
function, associated coronary artery disease, and visualize
the amount and distribution of valvular calcification. Supra-
aortic angiography is performed to establish the optimal pro-
jection for PHV deployment. This view (generally antero-pos-
terior) should profile the aortic valve and its annulus as well
as demonstrate the coronary ostia clearly. A frame is stored
for display on an adjacent monitor screen during the PHV
implant. Aortography with angiography of the iliac and femo-
ral arteries prior to the procedure, CT angiography, or MR
angiography of the aorta and pelvic vessels are necessary to
plan the strategy for a retrograde femoral artery approach or
antegrade trans-apical approach. 
Aspirin 160mg and clopidogrel 300 mg are given orally at
least 24 hours prior to the procedure. Antibiotic prophylaxis
is administered prior to and up to 48 h after the procedure.
Clopidogrel (75 mg/day) is continued for one month, and
aspirin (160 mg/day) indefinitely. 
Predilatation of the native valve
Common to each technique is BAV prior to PHV deployment
to prepare the native aortic valve and to facilitate its cros-
sing. This is achieved using a 23 mm diameter balloon (20 mm
diameter balloon in the case of a small calcified annulus)
and rapid ventricular pacing (RVP). RVP pacing was develo-
ped by Alain Cribier for optimal PHV delivery (figure 3). A
pacemaker lead is positioned in the right ventricle and used
to pace the heart at 180 to 220 beats per minute. RVP will
immediately lead to a drop in aortic blood pressure below
60 mmHg and a decrease in cardiac output allowing balloon
stabilization across the aortic valve. A brief period of RVP
(< 10 sec) is sufficient to inflate and deflate the balloon
(figure 3).
The antegrade trans-septal approach 
Technical steps related to this approach have been descri-
bed earlier [5, 6] and will not be detailed here. This
approach was used per protocol in 85% of patients included
in the feasibility trials I-REVIVE and RECAST and has not
been used in the recent multicenter trials.
The advantage of the antegrade approach is that it is
truly percutaneous and performed under local anesthe-
sia. This technique avoids the potential complications
related to small caliber diffusely diseased tortuous iliac
and femoral arteries encountered in the elderly. The PHV
assembly is positioned and deployed in the direction of
blood flow across the surface of the valve which is
usually less diseased, resulting in smoother passage and
greater stability. Failure to cross the native aortic valve
using the antegrade approach was never experienced.
Although the interatrial septum is crossed with a large
profile device problems with residual shunting were not
encountered. 
This approach is technically demanding and more complica-
ted than the retrograde approach. The antegrade technique
Figure 3. Effect of rapid pacing (200 beats/min) on aortic blood
pressure at the time of balloon inflation for valve delivery. 
Figure 4. Three phases of PHV implantation using the retrograde approach. A. the PHV has been advanced over a wire entering the femo-
ral artery and is positioned at the level of the native valve's calcifications. B. The PHV is delivered by balloon inflation under rapid pacing.
C. A supra-aortic angiogram is performed after PHV delivery to assess the degree of paravalvular leak (no regurgitation in this case).
B CA
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requires a significant learning curve limiting its widespread
use. Because of the complexity of the antegrade approach,
and the hemodynamic instability that can arise from inter-
ference or injury to the mitral valve if the guidewire is not
handled properly, there was renewed emphasis on refining
the retrograde approach. However, there will always be
patients with small caliber vessels, severe arterial tortuosi-
ties, obstructions of the femoral and iliac arteries, or
extensive atherosclerotic disease of the abdominal or aortic
arch who will need an antegrade approach.
The retrograde approach
This approach is the most frequent approach in the trials
since 2005. It was facilitated by the development of a spe-
cific catheter, the RetroFlex catheter described previously.
Femoral puncture, retrograde crossing of aortic
valve, pre-dilation of valve and femoral artery
Baseline measurements are obtained as described pre-
viously. In our center, the procedure is performed under
local anesthesia and mild sedation after surgical cut down
of the femoral artery and puncture. In the vast majority of
centers, the procedure is done under general anesthesia
and transesophageal echocardiographic (TEE) guidance.
The common femoral artery is either exposed surgically or
punctured percutaneously. 
After retrograde catheterization of the aortic valve, the
straight-tip 0.35 inch guidewire is exchanged for an extra
stiff guidewire, and pre-dilation of the aortic valve is done
as described previously. The femoral artery is then pre-dila-
ted with a series of dilators of increasing size (18F, 20F, and
22F) in order to facilitate entry of the 22 F or 24F sheath.
PHV delivery and deployment 
The PHV is advanced over the extra stiff guidewire, placed
within the native valve and deployed using RVP (figure 4).
Post-implantation hemodynamic (figure 5) and angiographic
measurements are performed with special attention to the
supra-aortic angiogram to assess any paravalvular leak. Arte-
rial access is managed by surgical repair in the cath-lab.
The retrograde approach's main advantage relies on its
similarities with routine BAV, a familiar technique for the
Interventional Cardiologists. Its main limitations center on
the arterial sheath size required for device insertion and the
lack of ability to reposition the prosthesis after deployment.
Clinical experience with the 
Cribier-PVT/Edwards bioprosthesis
Following the report of our first PHV implant [4], initial
patient series were selected on a compassionate basis after
being formally declined for valve replacement by two inde-
pendent cardiac surgeons. They were part of either the I-
REVIVE trial (using either the antegrade or retrograde
approach) or the RECAST trial (using solely the antegrade
approach) [5, 6]. From April 2006 through April 2007,
patients were included in the multicenter European trial
REVIVE (Registry of EndoVascular Implantation of Valves in
Europe). The follow-up of this study is ongoing and one-year
results are expected by mid-2008. Following the REVIVE
trial, the multicenter European PARTNER Trial has started
in July 2007. Results of these series will be detailed below.
Feasibility studies I-REVIVE and RECAST 
The results of this "first in man" series of patients initial
results have been published and will not be detailed here
[5, 6]. In summary, these studies demonstrated the feasi-
bility of the technique. Despite compassionate use in
36 patients, implantation success rate was high (85%) and
hemodynamic results were remarkable. Final AVA increased
from 0.60 ± 0.11cm2 to 1.70 ± 0.10 cm2, p < 0.0001 and resi-
dual gradient was negligible (< 10 mm Hg). There was no coro-
nary obstruction. Close clinical and echocardiographic follow-
up did not show any valve dysfunction or secondary valve
migration. Two patients are alive 4 years after implantation
with perfectly stable clinical and echocardiographic results.
Retrograde arterial approach studies
To enhance the effectiveness of the retrograde approach, a
lower profile system with better ability to traverse the vas-
cular system and aortic arch, as well as to overcome wire
bias and resistance to crossing the native valve was needed.
Furthermore, because of the concern of PHV migration and
paravalvular leaks, a larger diameter PHV was designed and
produced. These two major advances led to the revival of
the retrograde arterial trans-femoral approach. For regula-
tory reasons, these technologic advances could not be used
in France before 2006 and were evaluated initially by J.
Webb in Canada [8, 9]. The technique was also evaluated in
the United States in 55 patients in 3 centers included in the
REVIVAL II Trial.
Data on this retrograde transfemoral approach is growing
with more than 270 patients implanted as of October 2007.
After a preliminary series of 18 patients [8], Webb et al
recently reported the updated series of 50 patients [9]. Pro-
Figure 5. Transvalvular gradient at baseline (left) and after
(right) PHV implantation. The lack of gradient after PHV implanta-
tion is observed in each case.
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cedural success rate was high (86%) and the 30-day mortality
was 12%. His data also showed improvement following a lear-
ning curve of 25 procedures. The ongoing REVIVE trial in
Europe/Canada (> 85 patients implanted) and the REVIVAL II
trial in the US (55 patients implanted) are aimed at assessing
the acute and long term results using this new technology.
The results are very promising, currently similar to those
reported by John Webb. Implantation success rate is approxi-
mately 90% in all the series. Thirty-day mortality is 8% in the
REVIVAL II trial and 12% in the European REVIVE Trial. From
these results, there is no doubt that transarterial retrograde
PHV implantation represents a significant enhancement with
respect to delivery and procedural simplicity.
Further improvements are on the way. In order to facili-
tate advancement of the PHV assembly up to and then across
the stenotic aortic valve, a covered sheath delivery system
(Harmony, Edwards Lifesciences, Irvine, CA) has been deve-
loped and is under investigation in Canada. A decrease of 3
to 5F will probably allow a fully percutaneous procedure. An
increase in the width of the fabric sleeve sewn onto the
stent, another device improvement, allows a greater liberty
for prosthesis positioning across the calcified aortic valve. A
cobalt-chromium stent platform that will decrease the
device's profile is also foreseen in the near future.
The trans-apical approach
The feasibility of the transapical approach for PHV implanta-
tion was shown in an animal model, and has been recently
reported in humans [13-16]. In this approach, the same Cri-
bier-Edwards PHV and its delivery catheter are introduced
under direct vision into the left ventricle via a mini-thoraco-
tomy. After ventricular puncture they are directed across
the aortic valve under guidance of TEE and fluoroscopy. This
obviates the concerns regarding vascular access in the pre-
sence of small caliber vessels and/or vascular occlusive
disease. It potentially reduces the risk for stroke related to
passage of a stiff device through a diseased and tortuous
aorta to zero, as was seen in Walther’s recently published
series [16]. Patients with a “porcelain aorta”, previous car-
diac surgery, or mediastinal radiation may be suitable for
this approach. Currently, general anesthesia and mechanical
ventilation are required limiting the applicability in patients
with chronic lung disease or other disorders which would
contra-indicate general anesthesia. More than 200 patients
have been treated with this approach. In the European expe-
rience 30-day mortality is 14% (TCT 2007). Data on
59 patients from 4 centers were recently published [16]. In-
hospital mortality rate was 13.6% and actuarial survival was
75.7 ± 5.9% at a follow-up interval of 110 ± 77 days. Neither
coronary obstruction nor migration of the prosthesis was
observed, and all valves had good hemodynamic function.
In the future, the interventional cardiologist will have
several technical alternatives to ensure the procedural suc-
cess of PHV implantation, depending on various anatomic
and clinical features. 
Future strategies
Pulmonary valve and degenerated 
bioprosthetic valve
Placement of PHV technology in the pulmonary position has
been reported in animals [17]. Human implantation has
been reported once in an adolescent boy who had a prior
Ross procedure with subsequent replacement with a homo-
graft in the pulmonary position [18]. When the homograft
became stenotic, the patient had stenting of the pulmonary
valve followed by deployment of the Cribier-Edwards valve
with a successful result.
Balloon valvuloplasty has been carried out for stenotic
bioprosthetic valves in the aortic, tricuspid, or mitral posi-
tions [19-22]. Since the bioprosthetic “stent” can provide
the means of anchoring the PHV, there is future potential
for non-surgical management of bioprosthetic valve failure
with this balloon expandable device [23]. A surgical valve-
in-valve procedure has been performed in a patient with a
failed bioprosthetic mitral valve, suggesting the feasibility
of this approach [24].
The CoreValve and other competing 
technologies
There is intense interest in PHV technology, and there are
multiple devices at various stages of development in animals
and humans. The most developed is the CoreValve Reval-
ving® Technology. The first patient to be treated with this
technology was in 2004, 2 years after the first human implan-
tation with the Cribier-Edwards bioprosthesis. The CoreValve
PHV is a self-expanding nitinol stented porcine valve, which
is being developed for the treatment of aortic regurgitation
and AS. The stent has three parts: the lower portion with
high radial strength to keep the aortic valve leaflets open;
the middle part where the bioprosthesis lies; and the supe-
rior portion which flares into the ascending aorta and provi-
des longitudinal stability. The device was initially available
on a 24 F platform and was placed with extracorporeal circu-
lation. A second generation 21 F valve proceeded, which has
been currently replaced by an 18-F device which makes it a
truly percutaneous procedure. More than 350 patients have
been treated with this technique. The immediate and mid-
term results with this device are promising [10-12] with a
procedural success of 92% and a 30-day mortality of 15%.
However, the risk of stroke (5%–7%) and tamponade (7%) in
their recent series are non-negligible. Pacemaker implanta-
tion rate is also high at 16%-24% in recent series (TCT 2007).
The major advantages of the Corevalve prosthesis include a
smaller sheath size and the ability to reposition the valve
when it is partially deployed. This provides liberty to the
operator to optimize the valve if its position is not exact. The
higher incidence of stroke and permanent pacemaker requi-
rements illustrate its limitations.
Conclusion
The future of this technology and its application is depen-
dent on the continued collaboration between general
internists, cardiologists, surgeons, engineers, and industry.
Because there is a substantial learning curve with each of
the techniques and for each device, there must be collabo-
ration between cardiologists and cardiac surgeons in order
to disseminate the necessary knowledge and skills. Only a
portion of the technique can be taught in a lecture hall or
on a simulator. There is a fundamental knowledge, skill
set, and clinical wisdom of general physicians, imagers,
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interventionalists, and surgeons which must be shared,
coordinated, and in fact, synchronized to ensure successful
outcomes and future development of the new techniques.
Selecting the appropriate patients for surgical conventio-
nal aortic valve replacement, percutaneous valve implanta-
tion, balloon valvuloplasty, or palliative hospice care is
becoming more complex. This demands an attention to
individual patient’s desires regarding their quality and
quantity of life. A broader array of therapeutic options,
including PHV, for the treatment of these high risk and ino-
perable patients with severe calcific AS is within reach.
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